Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Vivos Therapeutics, Inc. (VVOS:NASDAQ), powered by AI.
Vivos Therapeutics, Inc. is currently trading at $0.54. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Vivos Therapeutics, Inc. on Alpha Lenz.
View Vivos Therapeutics, Inc.'s valuation metrics on Alpha Lenz.
“Vivos Therapeutics, Inc.'s ROE is -656.9%. Explore profitability and growth together.”
Ask for details →Vivos Therapeutics, Inc. is a medical technology company that concentrates on addressing sleep apnea through innovative treatment solutions. Primarily known for its proprietary systems and devices, the company offers a non-surgical approach designed to improve airway function and alleviate symptoms for patients suffering from obstructive sleep apnea (OSA), a common and often undiagnosed condition linked to various health issues. Operating at the intersection of medical devices and dental care, Vivos provides its solutions primarily to healthcare professionals, enabling them with tools and training necessary to effectively manage and treat sleep disorders. This focus on a non-invasive methodology has positioned Vivos as a notable player in the sleep disorder treatment market. Its approach not only aims to provide relief for individuals but also reduces dependency on traditional continuous positive airway pressure (CPAP) machines. Vivos Therapeutics plays a significant role in enhancing patient care within the healthcare sector by bridging the gap between dentistry and medicine, helping to raise awareness and offer alternative treatments for sleep-related breathing disorders.
“Vivos Therapeutics, Inc.'s ROE is -656.9%. Explore profitability and growth together.”
Ask for details →Vivos Therapeutics, Inc. (ticker: VVOS) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 113 employees.
The current price is $0.545 with a P/E ratio of -x and P/B of -x.
ROE is -656.87% and operating margin is -114.05%. Annual revenue is $17M.